GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cutera Inc (NAS:CUTR) » Definitions » Beneish M-Score

Cutera (Cutera) Beneish M-Score

: -2.02 (As of Today)
View and export this data going back to 2004. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.02 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Cutera's Beneish M-Score or its related term are showing as below:

CUTR' s Beneish M-Score Range Over the Past 10 Years
Min: -4.59   Med: -2.33   Max: 2.85
Current: -2.02

During the past 13 years, the highest Beneish M-Score of Cutera was 2.85. The lowest was -4.59. And the median was -2.33.


Cutera Beneish M-Score Historical Data

The historical data trend for Cutera's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutera Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.26 -2.78 -2.65 -2.16 -2.17

Cutera Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.12 -2.17 -1.73 -1.34 -2.02

Competitive Comparison

For the Medical Devices subindustry, Cutera's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cutera Beneish M-Score Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Cutera's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cutera's Beneish M-Score falls into.



Cutera Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cutera for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.4311+0.528 * 1.3762+0.404 * 1.0809+0.892 * 0.9182+0.115 * 0.5439
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2924+4.679 * 0.025062-0.327 * 1.3327
=-2.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was $54.5 Mil.
Revenue was 46.478 + 61.825 + 54.526 + 67.353 = $230.2 Mil.
Gross Profit was 6.457 + 26.083 + 21.632 + 38.749 = $92.9 Mil.
Total Current Assets was $311.3 Mil.
Total Assets was $406.6 Mil.
Property, Plant and Equipment(Net PPE) was $80.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.2 Mil.
Selling, General, & Admin. Expense(SGA) was $174.9 Mil.
Total Current Liabilities was $92.4 Mil.
Long-Term Debt & Capital Lease Obligation was $427.6 Mil.
Net Income was -44.274 + -33.278 + -28.048 + -7.788 = $-113.4 Mil.
Non Operating Income was -1.948 + -0.453 + -0.163 + -0.122 = $-2.7 Mil.
Cash Flow from Operations was -36.877 + -29.971 + -37.018 + -17.027 = $-120.9 Mil.
Total Receivables was $41.5 Mil.
Revenue was 62.808 + 64.224 + 58.014 + 65.629 = $250.7 Mil.
Gross Profit was 34.248 + 35.044 + 31.788 + 38.181 = $139.3 Mil.
Total Current Assets was $366.3 Mil.
Total Assets was $428.2 Mil.
Property, Plant and Equipment(Net PPE) was $47.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.9 Mil.
Selling, General, & Admin. Expense(SGA) was $147.4 Mil.
Total Current Liabilities was $98.3 Mil.
Long-Term Debt & Capital Lease Obligation was $312.6 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(54.512 / 230.182) / (41.482 / 250.675)
=0.236821 / 0.165481
=1.4311

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(139.261 / 250.675) / (92.921 / 230.182)
=0.555544 / 0.403685
=1.3762

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (311.307 + 80.613) / 406.633) / (1 - (366.312 + 47.512) / 428.157)
=0.036183 / 0.033476
=1.0809

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=230.182 / 250.675
=0.9182

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.933 / (1.933 + 47.512)) / (6.243 / (6.243 + 80.613))
=0.039094 / 0.071878
=0.5439

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(174.916 / 230.182) / (147.393 / 250.675)
=0.759903 / 0.587984
=1.2924

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((427.595 + 92.406) / 406.633) / ((312.583 + 98.258) / 428.157)
=1.278797 / 0.959557
=1.3327

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-113.388 - -2.686 - -120.893) / 406.633
=0.025062

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Cutera has a M-score of -2.02 suggests that the company is unlikely to be a manipulator.


Cutera (Cutera) Business Description

Traded in Other Exchanges
Address
3240 Bayshore Boulevard, Brisbane, CA, USA, 94005
Cutera Inc is a medical device company. It specializes in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States geographic segment.
Executives
Taylor C. Harris director 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Stuart Drummond officer: Interim Chief Financial Office C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Jeffrey S Jones officer: Chief Operating Officer C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Kevin J Cameron director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Keith J Sullivan director C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
David H Mowry director, officer: Chief Executive Officer 9775 TOLEDO, IRVINE CA 92618
Rohan Seth officer: Chief Financial Officer C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Timothy J Oshea director C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Juliane Park director C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Janet D. Widmann director 1411 E. MISSION AVENUE, SPOKANE WA 99202
J Daniel Plants director ONE EMBARCADERO CENTER, SUITE 1140, SAN FRANCISCO CA 94111
Katherine S Zanotti director 431 E 9TH STREET, HINSDALE IL 60521
Joseph E Whitters director
Sheila Hopkins director C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016